879993--3/11/2009--DUSA_PHARMACEUTICALS

related topics

{product, candidate, development}

{product, liability, claim}

{condition, economic, financial}

{property, intellectual, protect}

{stock, price, share}

{stock, price, operating}

{product, market, service}

{financial, litigation, operation}

{personnel, key, retain}

{control, financial, internal}

We Are Not Currently Profitable And May Not Be Profitable In The Future Unless We Can Successfully Market And Sell Significantly Higher Quantities Of Our Products. If Product Sales Do Not Continue to Increase, We May Not Be Able To Advance Development Of Our Other Potential Products As Quickly As We Would Like To, Which Would Delay The Approval Process And Marketing Of New Potential Products. Any Failure To Comply With Ongoing Governmental Regulations In The United States And Elsewhere Will Limit Our Ability To Market Our Products And Become Profitable. The Current Global Credit And Financial Market Conditions May Affect Our Business. If the Economic Slowdown Affects Our Market, Our Cash Burn Will Increase And Our Ability To Achieve Profitability Will Be Delayed. We Have Significant Losses And Anticipate Continued Losses. If We Are Unable To Obtain The Necessary Capital To Fund Our Operations, We Will Have To Delay Our Development Program And May Not Be Able To Complete Our Clinical Trials. If We Are Not Successful With The Reexamination Of Our Patent, We Could Lose Market Share. We Have Limited Patent Protection, And If We Are Unable To Protect Our Proprietary Rights, Competitors Might Be Able To Develop Similar Products To Compete With Our Products And Technology. Litigation Is Expensive And We May Not Be Able To Afford The Costs. Since We Now Operate The Only FDA Approved Manufacturing Facility For The Kerastick And Continue To Rely Heavily On Sole Suppliers For The Manufacture Of Levulan , The BLU-U , And Meted , Any Supply Or Manufacturing Problems Could Negatively Impact Our Sales As Occurred With Nicomide . We Have Only Limited Experience Marketing And Selling Pharmaceutical Products And No Experience Marketing Dietary Supplements, As A Result, Our Revenues From Product Sales May Suffer. The Commercial Success Of Any Product That We May Develop Will Depend Upon The Degree Of Market Acceptance Of Our Products Among Physicians, Patients, Health Care Payors, Private Health Insurers And The Medical Community. If We Cannot Improve Physician Reimbursement And/Or Convince More Private Insurance Carriers To Adequately Reimburse Physicians For Our Product, Sales May Suffer. We Have Only Three Therapies That Have Received Regulatory Approval Or Clearance, And We Cannot Predict Whether We Will Ever Develop Or Commercialize Any Other Levulan Products. Because Of The Nature Of Our Business, The Loss Of Key Members Of Our Management Team Could Delay Achievement Of Our Goals. Collaborations With Outside Scientists May Be Subject To Restriction And Change. Risks Related To Our Industry Product Liability And Other Claims Against Us May Reduce Demand For Our Products Or Result In Damages. We May Not Be Able To Compete Against Traditional Treatment Methods Or Keep Up With Rapid Changes In The Biotechnology And Pharmaceutical Industries That Could Make Some Or All Of Our Products Non-Competitive Or Obsolete. Risks Related To Our Stock Our Common Stock May Not Continue To Trade On The Nasdaq Global Market, Which Could Reduce The Value Of Your Investment And Make Your Shares More Difficult To Sell. Our Results Of Operations And General Market Conditions For Specialty Pharmaceutical And Biotechnology Stocks Could Result In Sudden Changes In The Market Value Of Our Stock. Significant Fluctuations In Orders For Our Products, On A Monthly And Quarterly Basis, Are Common Based On External Factors And Sales Promotion Activities. These Fluctuations Could Increase The Volatility Of Our Stock Price.

Full 10-K form ▸

879993--3/11/2009--DUSA_PHARMACEUTICALS_INC